西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2014年
8期
843-845
,共3页
阿替普酶%溶栓%ST段抬高型%心肌梗死%疗效
阿替普酶%溶栓%ST段抬高型%心肌梗死%療效
아체보매%용전%ST단태고형%심기경사%료효
alteplase(rt-PA)%thrombolysis%ST segment elevation%myocardial infarction%curative effect
目的：探讨阿替普酶（rt-PA）静脉溶栓治疗急性 ST 段抬高型心肌梗死的临床疗效和安全性。方法将我院2010年1月~2014年1月收治的126例 ST 段抬高型心肌梗死患者随机分为阿替普酶（rt-PA）组和尿激酶（UK）组，两组均在予阿斯匹林、氯吡格雷双联抗血小板、阿托伐他汀及其他常规治疗的基础上，分别给予阿替普酶及尿激酶溶栓治疗，比较两组总的冠脉开通率、胸痛缓解率、出血不良反应发生情况。结果 rt-PA 组的冠脉再通率为79.4%，明显高于 UK 组的54.0%（P ﹤0.05）；rt-PA 组的胸痛缓解率明显高于 UK 组（P ﹤0.05），而出血不良反应明显低于 UK 组（P ﹤0.05）。结论阿替普酶溶栓治疗急性 ST 段抬高型心肌梗死，比尿激酶具有更高的冠脉开通率，临床疗效更佳，出血不良反应更少，安全性好，更适合基层医院推广使用。
目的：探討阿替普酶（rt-PA）靜脈溶栓治療急性 ST 段抬高型心肌梗死的臨床療效和安全性。方法將我院2010年1月~2014年1月收治的126例 ST 段抬高型心肌梗死患者隨機分為阿替普酶（rt-PA）組和尿激酶（UK）組，兩組均在予阿斯匹林、氯吡格雷雙聯抗血小闆、阿託伐他汀及其他常規治療的基礎上，分彆給予阿替普酶及尿激酶溶栓治療，比較兩組總的冠脈開通率、胸痛緩解率、齣血不良反應髮生情況。結果 rt-PA 組的冠脈再通率為79.4%，明顯高于 UK 組的54.0%（P ﹤0.05）；rt-PA 組的胸痛緩解率明顯高于 UK 組（P ﹤0.05），而齣血不良反應明顯低于 UK 組（P ﹤0.05）。結論阿替普酶溶栓治療急性 ST 段抬高型心肌梗死，比尿激酶具有更高的冠脈開通率，臨床療效更佳，齣血不良反應更少，安全性好，更適閤基層醫院推廣使用。
목적：탐토아체보매（rt-PA）정맥용전치료급성 ST 단태고형심기경사적림상료효화안전성。방법장아원2010년1월~2014년1월수치적126례 ST 단태고형심기경사환자수궤분위아체보매（rt-PA）조화뇨격매（UK）조，량조균재여아사필림、록필격뢰쌍련항혈소판、아탁벌타정급기타상규치료적기출상，분별급여아체보매급뇨격매용전치료，비교량조총적관맥개통솔、흉통완해솔、출혈불량반응발생정황。결과 rt-PA 조적관맥재통솔위79.4%，명현고우 UK 조적54.0%（P ﹤0.05）；rt-PA 조적흉통완해솔명현고우 UK 조（P ﹤0.05），이출혈불량반응명현저우 UK 조（P ﹤0.05）。결론아체보매용전치료급성 ST 단태고형심기경사，비뇨격매구유경고적관맥개통솔，림상료효경가，출혈불량반응경소，안전성호，경괄합기층의원추엄사용。
Objective To explore the clinical effect of intravenous thrombolytic therapy with alteplase(rt-PA)on acute ST segment elevation myocardial infarction(STEMI)and the safety. Methods 126 cases with STEMI hospitalized in the period from Jan. , 2010 to Jan. ,2014 were randomly divided into 2 groups:group rt-PA and group UK;aspirin combined with clopidogrel for antiplatelet, atorvastatin and routine treatment were applied to cases in both groups,while thrombolytic therapy with rt-PA was added to cases in group rt-PA and thrombolytic therapy with urokinase was added to cases in group UK;a comparative study was made to the total coronary patency rate,the remission rate of chest pain,bleeding and other side effects between the 2 groups. Results The coronary patency rate in group rt-PA was 79. 4% ,much higher than that in group UK(54. 0% )(P ﹤0. 05);the remission rate of chest pain in group rt-PA was obviously higher than that in group UK(P ﹤0. 05),and the bleeding and other side effects in rt-PA group were less than those in group UK(P ﹤0. 05). Conclusions Alteplase thrombolytic therapy for acute STEMI is of higher coronary patency rate,better curative effect,less bleeding,less side effects and better safety than UK;it is more suitable for a wide application in primary hospitals.
